EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

Keijiro Yamauchi iD, Kinnosuke Matsumoto iD, Takayuki Shiroyama, Akihiro Tamiya, Motohiro Tamiya, Akihiro Tsukaguchi, Akito Miyazaki, Kiyohide Komuta, Yasuhiro Mihashi, Hirotomo Machiyama, Kensuke Kanaoka iD, Tomoki Kuge und 13 weitere

Thoracic Cancer · 2026-06 · 17 (11)

DOI: 10.1111/1759-7714.70317 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, online erschienen am 02.06.2026. Verfasst von Keijiro Yamauchi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan. Hauptthemen laut MEDLINE: Bevacizumab, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bevacizumab, an anti‐VEGF antibody, inhibits angiogenesis and modulates the tumor microenvironment. Because systemic inflammation is linked to VEGF activation and immune modulation, it may affect bevacizumab efficacy. However, this relationship remains unclear. We therefore evaluated whether systemic inflammation, assessed via the serum C‐reactive protein (CRP) level, modifies survival benefit when adding bevacizumab to chemoimmunotherapy in advanced non‐squamous non‐small cell lung cancer (NSCLC).

Methods

We retrospectively analyzed patients with advanced non‐squamous NSCLC from 13 Japanese institutions receiving first‐line atezolizumab plus chemotherapy with or without bevacizumab between December 2018 and December 2022. The primary endpoint was overall survival (OS). The interaction between CRP level (< 1 mg/dL vs. ≥ 1 mg/dL) and bevacizumab treatment was evaluated, and sensitivity analyses were performed to confirm the robustness of our findings.

Results

Among 193 eligible patients, 109 (56.5%) received bevacizumab. With a median follow‐up of 44.2 months, the median OS was 24.5 months in patients with low CRP and 17.3 months in those with high CRP (log‐rank test for trend, p = 0.04). Bevacizumab significantly improved OS in patients with high CRP (hazard ratio [HR] 0.63; 95% confidence interval, 0.40–0.99; p = 0.04), but not in those with low CRP (HR 1.22; p = 0.50). The interaction between CRP level and bevacizumab treatment was significant ( p = 0.033). Sensitivity analyses supported these results.

Conclusions

Systemic inflammation, as assessed by CRP level, may modify the efficacy of bevacizumab in advanced non‐squamous NSCLC. These hypothesis‐generating findings warrant prospective validation to clarify the role of CRP in treatment stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabCarcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedInflammationAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleMaleAgedMiddle AgedC-Reactive Protein

Stichwörter der Autor:innen

C‐reactive proteinatezolizumabbevacizumabpredictive biomarkersystemic inflammation

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabC-Reactive Protein

Autor:innen und Institutionen

  • Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
  • Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Osaka, Japan.
  • Department of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
  • Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center, Osaka, Japan.
  • Department of Immunogenomic Medicine, Research Institute, National Cancer Center, Tokyo, Japan.

ORCID-Profile: Keijiro Yamauchi, Kinnosuke Matsumoto, Kensuke Kanaoka, Satoshi Tanaka

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Yamauchi, K., Matsumoto, K., Shiroyama, T., Tamiya, A., Tamiya, M., Tsukaguchi, A., Miyazaki, A., Komuta, K., Mihashi, Y., Machiyama, H., Kanaoka, K., Kuge, T., Kinehara, Y., Shoshihara, N., Niki, T., Kato, S., Nishikawa, Y., Azuma, K., Tanaka, S., …, & Kumanogoh, A. (2026). Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study. Thoracic Cancer, 17(11). https://doi.org/10.1111/1759-7714.70317

Vancouver

Yamauchi K, Matsumoto K, Shiroyama T, Tamiya A, Tamiya M, Tsukaguchi A, et al. Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study. Thoracic Cancer. 2026;17(11). doi:10.1111/1759-7714.70317

BibTeX
@article{Yamauchi2026,
  author = {Yamauchi, Keijiro and Matsumoto, Kinnosuke and Shiroyama, Takayuki and Tamiya, Akihiro and Tamiya, Motohiro and Tsukaguchi, Akihiro and Miyazaki, Akito and Komuta, Kiyohide and Mihashi, Yasuhiro and Machiyama, Hirotomo and Kanaoka, Kensuke and Kuge, Tomoki and Kinehara, Yuhei and Shoshihara, Nao and Niki, Toshie and Kato, Soichiro and Nishikawa, Yuki and Azuma, Koji and Tanaka, Satoshi and Osa, Akio and Suzuki, Hidekazu and Nagatomo, Izumi and Uchida, Junji and Takeda, Yoshito and Kumanogoh, Atsushi},
  title = {Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {11},
  doi = {10.1111/1759-7714.70317}
}
Kostenlos starten →